Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
8-K
Regulation FD Disclosure
22 Feb 24
8-K
Other Events
20 Feb 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
Regulation FD Disclosure
3 Nov 23
EFFECT
Notice of effectiveness
18 Aug 23
424B5
Prospectus supplement for primary offering
17 Aug 23
CORRESP
Correspondence with SEC
15 Aug 23
UPLOAD
Letter from SEC
14 Aug 23
8-K
Other Events
11 Aug 23
S-3
Shelf registration
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
11 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
DEFA14A
Additional proxy soliciting materials
15 May 23
8-K
RAPT Therapeutics Reports First Quarter 2023 Financial Results
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
DEFA14A
Additional proxy soliciting materials
7 Apr 23
DEF 14A
Definitive proxy
7 Apr 23
S-8
Registration of securities for employees
14 Mar 23
8-K
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
14 Mar 23
10-K
2022 FY
Annual report
14 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Other Events
9 Jan 23
8-K
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy
12 Dec 22
8-K
Other Events
22 Nov 22
424B5
Prospectus supplement for primary offering
18 Nov 22
424B5
Prospectus supplement for primary offering
17 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
10 Nov 22
8-K
Transforming the Treatment of Cancer and Inflammation September 2022 Corporate Presentation
6 Sep 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
11 Aug 22
Latest ownership filings
4
Wendye Robbins
1 Apr 24
4
MARY ANN GRAY
1 Apr 24
4
WILLIAM JL RIEFLIN
1 Apr 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
WILLIAM HO
1 Feb 24
4
Rodney KB Young
1 Feb 24
4
Dirk G. Brockstedt
1 Feb 24
4
Brian Russell Wong
1 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Dirk G. Brockstedt
8 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
4
Dirk G. Brockstedt
2 Jan 24
4
WILLIAM HO
22 Dec 23
144
Notice of proposed sale of securities
21 Dec 23
4
WILLIAM HO
29 Nov 23
144
Notice of proposed sale of securities
28 Nov 23
SC 13G
Deep Track Capital, LP
23 Oct 23
4
WILLIAM HO
4 Oct 23
144
Notice of proposed sale of securities
3 Oct 23
4
WILLIAM HO
22 Aug 23
144
Notice of proposed sale of securities
18 Aug 23
4
WILLIAM HO
3 Aug 23
4
WILLIAM HO
27 Jun 23
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
12 Jun 23
4
Wendye Robbins
25 May 23
4
WILLIAM JL RIEFLIN
25 May 23
4
Lori Lyons-Williams
25 May 23
4
Linda Kozick
25 May 23
4
MARY ANN GRAY
25 May 23
4
Michael F Giordano
25 May 23
4
WILLIAM HO
20 Apr 23
144
Notice of proposed sale of securities
19 Apr 23
4
WILLIAM HO
14 Apr 23
4
WILLIAM JL RIEFLIN
10 Apr 23